Vaccines

Worldwide Cancer Vaccines Industry to 2025 - Analysis of Promising Vaccines

Friday, September 18, 2020 - 8:00pm

This report provides a comprehensive analysis of the fast-evolving, high-growth global cancer vaccines market.

Key Points: 
  • This report provides a comprehensive analysis of the fast-evolving, high-growth global cancer vaccines market.
  • The report offers the foremost up-to-date industry data on the specific market situation and future outlook for the global cancer vaccines market.
  • The report presents a clear perception of current and future developments of the global cancer vaccines market.
  • The report explores detailed insights into the introduction to cancer vaccines and the mechanism of cancer vaccines.

Axon Neuroscience to launch world's first crowdfunded vaccine against COVID-19

Friday, September 18, 2020 - 2:00pm

BRATISLAVA, Slovakia, Sept. 18, 2020 /PRNewswire/ -- AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 ACvac1.

Key Points: 
  • BRATISLAVA, Slovakia, Sept. 18, 2020 /PRNewswire/ -- AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 ACvac1.
  • With more than 20 years of experience developing an exceptionally safe and immunogenic peptide vaccine against dementia, in April 2020 Axon announced its plan to develop a novel peptide vaccine against COVID-19.
  • Michal Fresser, Chief Executive Officer of Axon said: "There is a global race for a vaccine.
  • The elderly can be overlooked by other vaccine developers in their push to find an effective vaccine quickly.

Axon Neuroscience to launch world's first crowdfunded vaccine against COVID-19

Friday, September 18, 2020 - 11:54am

BRATISLAVA, Slovakia, Sept. 18, 2020 /PRNewswire/ -- AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 ACvac1.

Key Points: 
  • BRATISLAVA, Slovakia, Sept. 18, 2020 /PRNewswire/ -- AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 ACvac1.
  • With more than 20 years of experience developing an exceptionally safe and immunogenic peptide vaccine against dementia, in April 2020 Axon announced its plan to develop a novel peptide vaccine against COVID-19.
  • Michal Fresser, Chief Executive Officer of Axon said: "There is a global race for a vaccine.
  • The elderly can be overlooked by other vaccine developers in their push to find an effective vaccine quickly.

Conjugate Vaccines Market| Insights on the Crisis and the Roadmap to Recovery from COVID-19 Pandemic| Technavio

Friday, September 18, 2020 - 10:45am
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200918005033/en/
    Technavio has announced its latest market research report titled Global Conjugate Vaccines Market 2020-2024 (Graphic: Business Wire)
    Get detailed insights on COVID-19 pandemic Crisis and Recovery analysis of the Conjugate Vaccines market.
  • Download free report sample
    Amid the COVID-19 Crisis, the Revaluated and Updated Conjugate Vaccines Market Report Says:
    The conjugate vaccines market will witness a Neutral and At par impact during the forecast period owing to the extensive rise of COVID-19 pandemic.
  • The conjugate vaccines market is segmented by type (multivalent conjugate vaccine and monovalent conjugate vaccine) and geography (Asia, Europe, North America, and ROW).
  • Increasing efforts for the stockpiling of conjugate vaccines has been an instrumental factor in influencing the growth of conjugate vaccines market.

Ufovax Announces Its Self-Assembling NanoParticles as the Next-Generation Vaccine Solution for COVID-19

Friday, September 18, 2020 - 12:32am

Ufovax holds an exclusive global license to the Scripps Intellectual Property covering the platform and several vaccines, including COVID-19.

Key Points: 
  • Ufovax holds an exclusive global license to the Scripps Intellectual Property covering the platform and several vaccines, including COVID-19.
  • In a publication submitted Monday, September 14 (now available on the bioRxiv preprint server ), the authors present a systematic study on rational vaccine design and evaluation of vaccine response in mice.
  • In particular, Zhu and his team propose a new spike antigen design (S2GHR2) and displayed it on several SApNPs as COVID-19 vaccine candidates.
  • In practice, we have seen similar performance from the Merck HPV Gardasil vaccine which is essentially a protein nanoparticle vaccine.

Healthvana Introduces Patient Platform to Support CDC’s COVID-19 Vaccination Playbook

Thursday, September 17, 2020 - 5:28pm

Healthvana, Inc. , the nations largest patient platform for COVID-19 and HIV test results, today announced its new mobile vaccination record and patient follow-up solution to support the CDC COVID-19 vaccination playbook released on September 16, 2020.

Key Points: 
  • Healthvana, Inc. , the nations largest patient platform for COVID-19 and HIV test results, today announced its new mobile vaccination record and patient follow-up solution to support the CDC COVID-19 vaccination playbook released on September 16, 2020.
  • Healthvana provides a single mobile platform for patients to access vaccination records, as well as ongoing SMS communications reminding them of their follow-up appointment and next steps for a successful vaccination.
  • The Healthvana platform will clearly show flu vaccinations in the same mobile dashboard as COVID-19 vaccinations.
  • Since 2015, the mobile-first patient platform has been rooted in empathy, enabling HIPAA-compliant test results to be easily and quickly distributed to patients.

Cervical Cancer Market is Expected to Increase With a CAGR of 16.9% for the Study Period of 2017-2030 in 7MM: DelveInsight

Thursday, September 17, 2020 - 3:30pm

An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.

Key Points: 
  • An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.
  • Some of the key insights from cervical cancer market report:
    The incidence of cervical cancer in 7MM (US, UK, Germany, Italy, Spain, France & Japan) in 2020 is expected to be 43,712.
  • Get a cervical cancer sample copy or download a cervical cancer infograph: www.delveinsight.com/sample-request/cervical-cancer-market
    Cervical cancer is a cause of infection from Human papillomavirus (HPV), which can be prevented.
  • The cervical cancer market also homes Merck's star, Keytruda, which got approval in 2018 for advanced cervical cancer for PD-L1 positive patients.

Cervical Cancer Market is Expected to Increase With a CAGR of 16.9% for the Study Period of 2017-2030 in 7MM: DelveInsight

Thursday, September 17, 2020 - 3:30pm

An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.

Key Points: 
  • An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.
  • Some of the key insights from cervical cancer market report:
    The incidence of cervical cancer in 7MM (US, UK, Germany, Italy, Spain, France & Japan) in 2020 is expected to be 43,712.
  • Get a cervical cancer sample copy or download a cervical cancer infograph: www.delveinsight.com/sample-request/cervical-cancer-market
    Cervical cancer is a cause of infection from Human papillomavirus (HPV), which can be prevented.
  • The cervical cancer market also homes Merck's star, Keytruda, which got approval in 2018 for advanced cervical cancer for PD-L1 positive patients.

Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?

Thursday, September 17, 2020 - 2:17pm

ET to discuss the concept of two types of immune responses antibody vs. T Cell as well as provide an overview of the challenges of developing an effective vaccine.

Key Points: 
  • ET to discuss the concept of two types of immune responses antibody vs. T Cell as well as provide an overview of the challenges of developing an effective vaccine.
  • Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?
  • Tonixs lead vaccine candidate, TNX-1800*, is a live replicating, attenuated vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response.
  • Tonix is also developing TNX-2300* and TNX-2600*, live replicating vaccine candidates for the prevention of COVID-19, but using bovine parainfluenza as the vector.

Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID

Thursday, September 17, 2020 - 2:30pm

This second group of eight participants received a single escalated dose of either AT-301A (placebo) or AT-301B (active drug).

Key Points: 
  • This second group of eight participants received a single escalated dose of either AT-301A (placebo) or AT-301B (active drug).
  • Based on rapid enrollment in the first half of the study, we expect to complete enrollment in the remainder of the study very quickly.
  • We anticipate that our AT-301 nasal spray will complement any traditional COVID-19 vaccine that may be developed, added Dr. Quay.
  • The ongoing Phase 1 study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups.